Phase III Daclatasvir and Sofosbuvir for Genotype 3 Chronic HCV

PHASE3CompletedINTERVENTIONAL
Enrollment

173

Participants

Timeline

Start Date

January 31, 2014

Primary Completion Date

September 30, 2014

Study Completion Date

December 31, 2014

Conditions
Hepatitis C
Interventions
DRUG

Daclatasvir

DRUG

Sofosbuvir

Trial Locations (31)

11030

North Shore University Hospital, Manhasset

12601

Premier Medical Group Of The Hudson Valley, Pc, Poughkeepsie

15213

Center For Liver Diseases, Pittsburgh

18944

Main Line Gastroenterology Associates Pc, Perkasie

21202

Mercy Medical Center, Inc., Baltimore

21229

Digestive Disease Associates, P.A., Baltimore

22042

Inova Fairfax Hospital, Falls Church

27103

Digestive Health Specialists, PA, Winston-Salem

28801

Asheville Gastroenterology Associates, PA, Asheville

30060

Gastrointestinal Specialists Of Georgia, Marietta

30308

Atlanta Gastroenterology Associates, Atlanta

32610

University of Florida Hepatology Research, Gainesville

32720

Midland Florida Clinical Research Center, LLC, DeLand

38138

Gastro One, Germantown

60515

Dupage Medical Group, Downers Grove

64131

Kansas City Research Institute, Kansas City

76012

Texas Clinical Research Institute, LLC, Arlington

78215

American Research Corporation, San Antonio

84106

Lifetree Clinical Research, Salt Lake City

84123

Clinical Research Centers Of America, Murray

87505

Southwest Care Center, Santa Fe

90036

Peter J Ruane MD Inc, Los Angeles

90057

National Research Institute, Los Angeles

90069

Anthony M. Mills MD Inc, Los Angeles

91105

Huntington Medical Research Institutes, Pasadena

92037

Scripps Clinic, La Jolla

92114

Precision Research Institute, LLC, San Diego

92123

Medical Associates Research Group, San Diego

94115

Quest Clinical Research, San Francisco

98101

Virginia Mason Medical Center, Seattle

00927

Fundacion De Investigacion De Diego, San Juan

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY